Radioembolization Versus Chemoembolization for Neuroendocrine Metastases

In the October 2020 issue of JVIR, Currie et  al (1) describe their experience with chronic hepatotoxicity after hepatic arterial directed therapy for hepatic metastatic neuroendocrine tumors (NET). They conclude that delayed hepatotoxicity occurs in 22% of patients treated with chemoembolization and 29% of patients treated with radioemboliza tion. This is certainly an essential investigation, as debate continues as to the optimal locoregional therapy for neuroendocrine hepatic metastases. Furthermore, with the advent of peptide receptor radiotherapy, preservation of hepatic function is paramount for patients to remain candidates for sub sequent treatment options.

Source: Journal of Vascular and Interventional Radiology : JVIR - December 26, 2020 Category: Radiology Authors: Siddharth A. Padia Tags: Letter to the Editor Source Type: research